Antibody response to Haemophilus influenzae type b tetanus conjugate vaccine with two doses given at 3 and 5 months of age.
Identifieur interne : 000242 ( Main/Exploration ); précédent : 000241; suivant : 000243Antibody response to Haemophilus influenzae type b tetanus conjugate vaccine with two doses given at 3 and 5 months of age.
Auteurs : Thais Guimarães [Brésil] ; Rosângela F. Cereda ; Paulo J. Bianchin ; Aparecida T. Nagao ; Magda C. Sampaio ; João S. MendonçaSource :
- International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [ 1201-9712 ] ; 2002.
Descripteurs français
- KwdFr :
- Anatoxine tétanique (administration et posologie), Anatoxine tétanique (immunologie), Anticorps antibactériens (immunologie), Brésil, Calendrier vaccinal, Facteurs temps, Femelle, Haemophilus influenzae (immunologie), Humains, Mâle, Nourrisson, Synergie des médicaments, Vaccin diphtérie-tétanos-coqueluche (administration et posologie), Vaccin diphtérie-tétanos-coqueluche (immunologie), Vaccins anti-Haemophilus (administration et posologie), Vaccins anti-Haemophilus (immunologie), Vaccins combinés, Vaccins conjugués (administration et posologie), Vaccins conjugués (immunologie).
- MESH :
- administration et posologie : Anatoxine tétanique, Vaccin diphtérie-tétanos-coqueluche, Vaccins anti-Haemophilus, Vaccins conjugués.
- immunologie : Anatoxine tétanique, Anticorps antibactériens, Haemophilus influenzae, Vaccin diphtérie-tétanos-coqueluche, Vaccins anti-Haemophilus, Vaccins conjugués.
- Brésil, Calendrier vaccinal, Facteurs temps, Femelle, Humains, Mâle, Nourrisson, Synergie des médicaments, Vaccins combinés.
- Wicri :
- geographic : Brésil.
English descriptors
- KwdEn :
- Antibodies, Bacterial (immunology), Brazil, Diphtheria-Tetanus-Pertussis Vaccine (administration & dosage), Diphtheria-Tetanus-Pertussis Vaccine (immunology), Drug Synergism, Female, Haemophilus Vaccines (administration & dosage), Haemophilus Vaccines (immunology), Haemophilus influenzae (immunology), Humans, Immunization Schedule, Infant, Male, Tetanus Toxoid (administration & dosage), Tetanus Toxoid (immunology), Time Factors, Vaccines, Combined, Vaccines, Conjugate (administration & dosage), Vaccines, Conjugate (immunology).
- MESH :
- chemical , administration & dosage : Diphtheria-Tetanus-Pertussis Vaccine, Haemophilus Vaccines, Tetanus Toxoid, Vaccines, Conjugate.
- chemical , immunology : Antibodies, Bacterial, Diphtheria-Tetanus-Pertussis Vaccine, Haemophilus Vaccines, Tetanus Toxoid, Vaccines, Conjugate.
- geographic : Brazil, Vaccines, Combined.
- immunology : Haemophilus influenzae.
- Drug Synergism, Female, Humans, Immunization Schedule, Infant, Male, Time Factors.
Abstract
BACKGROUND
In developed countries, the use of Hib conjugate vaccines has led to the near disappearance of invasive Hib disease, but costs have limited its use in developing countries. In order to identify more economical vaccination schedules, we carried out a trial to evaluate the immunogenicity of an alternative two-dose PRP-T regimen, based on a previous report in which carrier priming could be obtained with prior diphtheria-tetanus-pertussis (DTP) vaccination.
METHODS
Healthy infants were enrolled to receive the PRP-T given at 3 and 5 months of age, with DTP vaccination given at 2, 4 and 6 months of age. Serum specimens were obtained at 3, 6 and 15 months of age. IgG anti-Hib titer determination was performed using enzyme-linked immunosorbent assay to evaluate serologic response and its duration.
RESULTS
One-hundred and seventeen infants were enrolled. The geometric mean titer (GMT) of antibody to PRP was low in the pre-immunization samples (0.13 mg/mL), achieving high values after two doses of PRP-T (27.42 mg/mL), with all titers over 1 mg/mL; the GMT at 15 months was 5.45 mg/mL; 94.6% of infants had serologic responses after the two doses of vaccination, with average intervals of 27 and 22 days between DTP and PRP-T first-to-first and second-to-second administrations, respectively. However, these intervals were 11 and 3 days for infants who did not have serologic responses (P50.0013 and 0.0030, respectively).
CONCLUSIONS
These results indicate that two doses of PRP-T can induce high antibody titers using the proposed schedule; moreover, the GMT assessed at 15 months of age was also protective. The enhanced immune response observed in the study could be explained by the previous administration of the DTP vaccine, since the longer the interval between DTP and PRP-T, the better the response to Hib vaccine. The PRP-T vaccine given at 3 and 5 months of age may be an economical alternative to the current proposed schedule, which could make the introduction of Hib vaccination in developing countries more feasible, considering the relatively high cost of this vaccine.
DOI: 10.1016/s1201-9712(02)90071-8
PubMed: 12121598
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antibody response to Haemophilus influenzae type b tetanus conjugate vaccine with two doses given at 3 and 5 months of age.</title><author><name sortKey="Guimaraes, Thais" sort="Guimaraes, Thais" uniqKey="Guimaraes T" first="Thais" last="Guimarães">Thais Guimarães</name><affiliation wicri:level="1"><nlm:affiliation>Section of Vaccination, Infectious Diseases Service, Hospital do Servidor Público Estadual de São Paulo, Brazil. tguimaraes@terra.com.br</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Section of Vaccination, Infectious Diseases Service, Hospital do Servidor Público Estadual de São Paulo</wicri:regionArea><wicri:noRegion>Hospital do Servidor Público Estadual de São Paulo</wicri:noRegion></affiliation></author><author><name sortKey="Cereda, Rosangela F" sort="Cereda, Rosangela F" uniqKey="Cereda R" first="Rosângela F" last="Cereda">Rosângela F. Cereda</name></author><author><name sortKey="Bianchin, Paulo J" sort="Bianchin, Paulo J" uniqKey="Bianchin P" first="Paulo J" last="Bianchin">Paulo J. Bianchin</name></author><author><name sortKey="Nagao, Aparecida T" sort="Nagao, Aparecida T" uniqKey="Nagao A" first="Aparecida T" last="Nagao">Aparecida T. Nagao</name></author><author><name sortKey="Sampaio, Magda C" sort="Sampaio, Magda C" uniqKey="Sampaio M" first="Magda C" last="Sampaio">Magda C. Sampaio</name></author><author><name sortKey="Mendonca, Joao S" sort="Mendonca, Joao S" uniqKey="Mendonca J" first="João S" last="Mendonça">João S. Mendonça</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12121598</idno><idno type="pmid">12121598</idno><idno type="doi">10.1016/s1201-9712(02)90071-8</idno><idno type="wicri:Area/Main/Corpus">000326</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000326</idno><idno type="wicri:Area/Main/Curation">000326</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000326</idno><idno type="wicri:Area/Main/Exploration">000326</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antibody response to Haemophilus influenzae type b tetanus conjugate vaccine with two doses given at 3 and 5 months of age.</title><author><name sortKey="Guimaraes, Thais" sort="Guimaraes, Thais" uniqKey="Guimaraes T" first="Thais" last="Guimarães">Thais Guimarães</name><affiliation wicri:level="1"><nlm:affiliation>Section of Vaccination, Infectious Diseases Service, Hospital do Servidor Público Estadual de São Paulo, Brazil. tguimaraes@terra.com.br</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Section of Vaccination, Infectious Diseases Service, Hospital do Servidor Público Estadual de São Paulo</wicri:regionArea><wicri:noRegion>Hospital do Servidor Público Estadual de São Paulo</wicri:noRegion></affiliation></author><author><name sortKey="Cereda, Rosangela F" sort="Cereda, Rosangela F" uniqKey="Cereda R" first="Rosângela F" last="Cereda">Rosângela F. Cereda</name></author><author><name sortKey="Bianchin, Paulo J" sort="Bianchin, Paulo J" uniqKey="Bianchin P" first="Paulo J" last="Bianchin">Paulo J. Bianchin</name></author><author><name sortKey="Nagao, Aparecida T" sort="Nagao, Aparecida T" uniqKey="Nagao A" first="Aparecida T" last="Nagao">Aparecida T. Nagao</name></author><author><name sortKey="Sampaio, Magda C" sort="Sampaio, Magda C" uniqKey="Sampaio M" first="Magda C" last="Sampaio">Magda C. Sampaio</name></author><author><name sortKey="Mendonca, Joao S" sort="Mendonca, Joao S" uniqKey="Mendonca J" first="João S" last="Mendonça">João S. Mendonça</name></author></analytic><series><title level="j">International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</title><idno type="ISSN">1201-9712</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Bacterial (immunology)</term><term>Brazil</term><term>Diphtheria-Tetanus-Pertussis Vaccine (administration & dosage)</term><term>Diphtheria-Tetanus-Pertussis Vaccine (immunology)</term><term>Drug Synergism</term><term>Female</term><term>Haemophilus Vaccines (administration & dosage)</term><term>Haemophilus Vaccines (immunology)</term><term>Haemophilus influenzae (immunology)</term><term>Humans</term><term>Immunization Schedule</term><term>Infant</term><term>Male</term><term>Tetanus Toxoid (administration & dosage)</term><term>Tetanus Toxoid (immunology)</term><term>Time Factors</term><term>Vaccines, Combined</term><term>Vaccines, Conjugate (administration & dosage)</term><term>Vaccines, Conjugate (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anatoxine tétanique (administration et posologie)</term><term>Anatoxine tétanique (immunologie)</term><term>Anticorps antibactériens (immunologie)</term><term>Brésil</term><term>Calendrier vaccinal</term><term>Facteurs temps</term><term>Femelle</term><term>Haemophilus influenzae (immunologie)</term><term>Humains</term><term>Mâle</term><term>Nourrisson</term><term>Synergie des médicaments</term><term>Vaccin diphtérie-tétanos-coqueluche (administration et posologie)</term><term>Vaccin diphtérie-tétanos-coqueluche (immunologie)</term><term>Vaccins anti-Haemophilus (administration et posologie)</term><term>Vaccins anti-Haemophilus (immunologie)</term><term>Vaccins combinés</term><term>Vaccins conjugués (administration et posologie)</term><term>Vaccins conjugués (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diphtheria-Tetanus-Pertussis Vaccine</term><term>Haemophilus Vaccines</term><term>Tetanus Toxoid</term><term>Vaccines, Conjugate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Bacterial</term><term>Diphtheria-Tetanus-Pertussis Vaccine</term><term>Haemophilus Vaccines</term><term>Tetanus Toxoid</term><term>Vaccines, Conjugate</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Brazil</term><term>Vaccines, Combined</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anatoxine tétanique</term><term>Vaccin diphtérie-tétanos-coqueluche</term><term>Vaccins anti-Haemophilus</term><term>Vaccins conjugués</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anatoxine tétanique</term><term>Anticorps antibactériens</term><term>Haemophilus influenzae</term><term>Vaccin diphtérie-tétanos-coqueluche</term><term>Vaccins anti-Haemophilus</term><term>Vaccins conjugués</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Haemophilus influenzae</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Synergism</term><term>Female</term><term>Humans</term><term>Immunization Schedule</term><term>Infant</term><term>Male</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Brésil</term><term>Calendrier vaccinal</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Nourrisson</term><term>Synergie des médicaments</term><term>Vaccins combinés</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Brésil</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>In developed countries, the use of Hib conjugate vaccines has led to the near disappearance of invasive Hib disease, but costs have limited its use in developing countries. In order to identify more economical vaccination schedules, we carried out a trial to evaluate the immunogenicity of an alternative two-dose PRP-T regimen, based on a previous report in which carrier priming could be obtained with prior diphtheria-tetanus-pertussis (DTP) vaccination.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Healthy infants were enrolled to receive the PRP-T given at 3 and 5 months of age, with DTP vaccination given at 2, 4 and 6 months of age. Serum specimens were obtained at 3, 6 and 15 months of age. IgG anti-Hib titer determination was performed using enzyme-linked immunosorbent assay to evaluate serologic response and its duration.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>One-hundred and seventeen infants were enrolled. The geometric mean titer (GMT) of antibody to PRP was low in the pre-immunization samples (0.13 mg/mL), achieving high values after two doses of PRP-T (27.42 mg/mL), with all titers over 1 mg/mL; the GMT at 15 months was 5.45 mg/mL; 94.6% of infants had serologic responses after the two doses of vaccination, with average intervals of 27 and 22 days between DTP and PRP-T first-to-first and second-to-second administrations, respectively. However, these intervals were 11 and 3 days for infants who did not have serologic responses (P50.0013 and 0.0030, respectively).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>These results indicate that two doses of PRP-T can induce high antibody titers using the proposed schedule; moreover, the GMT assessed at 15 months of age was also protective. The enhanced immune response observed in the study could be explained by the previous administration of the DTP vaccine, since the longer the interval between DTP and PRP-T, the better the response to Hib vaccine. The PRP-T vaccine given at 3 and 5 months of age may be an economical alternative to the current proposed schedule, which could make the introduction of Hib vaccination in developing countries more feasible, considering the relatively high cost of this vaccine.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12121598</PMID><DateCompleted><Year>2002</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1201-9712</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int. J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Antibody response to Haemophilus influenzae type b tetanus conjugate vaccine with two doses given at 3 and 5 months of age.</ArticleTitle><Pagination><MedlinePgn>113-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In developed countries, the use of Hib conjugate vaccines has led to the near disappearance of invasive Hib disease, but costs have limited its use in developing countries. In order to identify more economical vaccination schedules, we carried out a trial to evaluate the immunogenicity of an alternative two-dose PRP-T regimen, based on a previous report in which carrier priming could be obtained with prior diphtheria-tetanus-pertussis (DTP) vaccination.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Healthy infants were enrolled to receive the PRP-T given at 3 and 5 months of age, with DTP vaccination given at 2, 4 and 6 months of age. Serum specimens were obtained at 3, 6 and 15 months of age. IgG anti-Hib titer determination was performed using enzyme-linked immunosorbent assay to evaluate serologic response and its duration.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One-hundred and seventeen infants were enrolled. The geometric mean titer (GMT) of antibody to PRP was low in the pre-immunization samples (0.13 mg/mL), achieving high values after two doses of PRP-T (27.42 mg/mL), with all titers over 1 mg/mL; the GMT at 15 months was 5.45 mg/mL; 94.6% of infants had serologic responses after the two doses of vaccination, with average intervals of 27 and 22 days between DTP and PRP-T first-to-first and second-to-second administrations, respectively. However, these intervals were 11 and 3 days for infants who did not have serologic responses (P50.0013 and 0.0030, respectively).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results indicate that two doses of PRP-T can induce high antibody titers using the proposed schedule; moreover, the GMT assessed at 15 months of age was also protective. The enhanced immune response observed in the study could be explained by the previous administration of the DTP vaccine, since the longer the interval between DTP and PRP-T, the better the response to Hib vaccine. The PRP-T vaccine given at 3 and 5 months of age may be an economical alternative to the current proposed schedule, which could make the introduction of Hib vaccination in developing countries more feasible, considering the relatively high cost of this vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guimarães</LastName><ForeName>Thais</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Section of Vaccination, Infectious Diseases Service, Hospital do Servidor Público Estadual de São Paulo, Brazil. tguimaraes@terra.com.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cereda</LastName><ForeName>Rosângela F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Bianchin</LastName><ForeName>Paulo J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Nagao</LastName><ForeName>Aparecida T</ForeName><Initials>AT</Initials></Author><Author ValidYN="Y"><LastName>Sampaio</LastName><ForeName>Magda C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Mendonça</LastName><ForeName>João S</ForeName><Initials>JS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000907">Antibodies, Bacterial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015721">Diphtheria-Tetanus-Pertussis Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018073">Haemophilus Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C055753">Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013745">Tetanus Toxoid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018074">Vaccines, Conjugate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000907" MajorTopicYN="N">Antibodies, Bacterial</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015721" MajorTopicYN="N">Diphtheria-Tetanus-Pertussis Vaccine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018073" MajorTopicYN="N">Haemophilus Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006193" MajorTopicYN="N">Haemophilus influenzae</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013745" MajorTopicYN="N">Tetanus Toxoid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018074" MajorTopicYN="N">Vaccines, Conjugate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>7</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>8</Month><Day>22</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>7</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12121598</ArticleId><ArticleId IdType="pii">S1201-9712(02)90071-8</ArticleId><ArticleId IdType="doi">10.1016/s1201-9712(02)90071-8</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Brésil</li></country></list><tree><noCountry><name sortKey="Bianchin, Paulo J" sort="Bianchin, Paulo J" uniqKey="Bianchin P" first="Paulo J" last="Bianchin">Paulo J. Bianchin</name><name sortKey="Cereda, Rosangela F" sort="Cereda, Rosangela F" uniqKey="Cereda R" first="Rosângela F" last="Cereda">Rosângela F. Cereda</name><name sortKey="Mendonca, Joao S" sort="Mendonca, Joao S" uniqKey="Mendonca J" first="João S" last="Mendonça">João S. Mendonça</name><name sortKey="Nagao, Aparecida T" sort="Nagao, Aparecida T" uniqKey="Nagao A" first="Aparecida T" last="Nagao">Aparecida T. Nagao</name><name sortKey="Sampaio, Magda C" sort="Sampaio, Magda C" uniqKey="Sampaio M" first="Magda C" last="Sampaio">Magda C. Sampaio</name></noCountry><country name="Brésil"><noRegion><name sortKey="Guimaraes, Thais" sort="Guimaraes, Thais" uniqKey="Guimaraes T" first="Thais" last="Guimarães">Thais Guimarães</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeBresilV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000242 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000242 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeBresilV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:12121598
|texte= Antibody response to Haemophilus influenzae type b tetanus conjugate vaccine with two doses given at 3 and 5 months of age.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:12121598" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeBresilV1
| This area was generated with Dilib version V0.6.35. |  |